A Phase I, Open-Label, Multi-Center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 Hyd-Sulfate When Given in Combination with Standard Doses of Selected Chemotherapies to Patients with Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Selumetinib (Primary) ; Dacarbazine; Docetaxel; Erlotinib; Temsirolimus
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 20 Dec 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 31 Aug 2018 Biomarkers information updated
- 07 Feb 2018 Planned End Date changed from 29 Dec 2017 to 31 Dec 2018.